Introduction
============

*Cryptococcus* spp. are basidiomycetous yeasts considered as the responsible agents for a wide range of diseases, among which *C.* *neoformans* and *C. gattii* are mentioned as the most common pathogenic species \[[@B1]-[@B3]\]. However, the incidence of infection due to non-neoformans cryptococcal species such as *Papiliotrema laurentii*(formerly*C. laurentii*) and *Naganishia albida* has increased recently \[[@B4], [@B5]\]. *N. albida* is an encapsulated yeast occasionally detected on human skin, air, and soil \[[@B6], [@B7]\].

Some cases of infection caused by *N. albida* such as keratitis, pneumonia, encephalitis, and cutaneous and disseminated cryptococcosis have been reported \[[@B8]-[@B10]\]. The treatment regimen for systemic cryptococcosis is amphotericin B in combination with flucytosine followed by fluconazole as consolidation therapy \[[@B8], [@B11], [@B12]\]. To date, there is no defined treatment for superficial cryptococcal infection. In the current study, we presented the first case of superficial cutaneous infection caused by *N. albida*, as well as its successful treatment with 100 mg daily of oral itraconazole. To the best of our knowledge, this is the first report on superficial cutaneous infection due to *N. albida*.

Case report
===========

A 26-year-old Iranian man without any underlying diseases was referred to Razi Hospital, a referral center for skin diseases in Iran that is affiliated to Tehran University of Medical Sciences, with a hyperpigmented patch in the axilla. Based on clinical examination, the diagnosis was made as pityriasis versicolor. However, treatment with clotrimazole cream was not successful and he returned to the hospital after one month.

Direct microscopic examination of the scales after mixing with 10% potassium hydroxide revealed the presence of yeast cells. Furthermore, the scales cultured on Dixon Agar (Quelab, Canada) plates for five days at 32°C produced white and creamy colonies with smooth surfaces. By Lactophenol Cotton Blue Staining of the smears, yeast cells similar to *Cryptococcus* were observed under microscope ([Figure 1](#F1){ref-type="fig"}).

![Macroscopic (A) and microscopic (B) demonstration of *N. albida*, which was indicated as the causative agent of superficial infection in the present case](cmm-3-033-g001){#F1}

Genomic DNA was extracted from culture using glass beads method \[[@B13]\], and polymerase chain reaction (PCR) was performed using universal primers \[[@B14]\] of ITS1 (5\'-TCC GTA GGT GAA CCT GCG G-3\') and ITS4 (5\'-TCC TCC GCT TAT TGA TAT GC-3\') (Sinaclon, Iran). The PCR product with the approximate size of 600 bp was applied for sequencing (Macrogen, South Korea). Alignment of the obtained sequence in BLAST revealed high homology (99%) with *N. albida*, which is indicated with GenBank ID: MG020697.1.

In the following step, the minimum inhibitory concentration (MIC) values for itraconazole, voriconazole, and amphotericin B were determined using the microbroth dilution method according to the Clinical Laboratory Standards Institute (CLSI) standard protocols \[[@B15]\]. Briefly, the test was performed in 96-well round-bottom microtiter plates. Drug concentration ranges were 0.03 to 16 µg/ml for itraconazole, voriconazole, and amphotericin B. Yeast suspensions were prepared in RPMI-1640 medium and adjusted to provide a final inoculum concentration of about 0.5 × 10^3^ to 2.5 × 10^3^ cells/ml. The culture plates were then incubated at 35°C followed by reading after 48 h according to the M27-S3 supplement of the CLSI guideline \[[@B15]\]. The MIC results were then compared with a drug-free control culture plate.

The MIC values for itraconazole, voriconazole, and amphotericin B were 0.062 µg/ml, 0.062 µg/ml, and 0.062 µg/ml, respectively, revealing the sensitivity of the mentioned causative agent. The patient was finally treated successfully using 100 mg daily of oral itraconazole. The Ethics Committee of Tehran University of Medical Sciences approved this report with the code No. IR.TUMS.SPH.REC.1396.2400.

Discussion
==========

*N. albida* is a non-neoformans species of the genus *Cryptococcus* with a similar morphology to *C. neoformans*. However, they can be differentiated by their reaction to biochemical tests such as phenol oxidase and color changes in Bird Seed Agar medium \[9, 16-19\]. In addition, *N. albida* is an opportunistic and encapsulated yeast found on human skin \[6, 7\]. Although *N. albida* rarely causes any diseases, there have been some case reports, including cases of meningitis, peritonitis, fungaemia, pulmonary and cutaneous infections, and keratitis ([Table 1](#T1){ref-type="table"}).

Moreover, cases of encephalitis, disseminated cryptococcosis, and pneumonia have been reported \[[@B4], [@B8], [@B20]-[@B29]\]. However, *N. albida* has never been reported as the causative agent of a superficial skin infection ([Table 1](#T1){ref-type="table"}). As can be observed in this table, the majority of reported cases were from the USA, whereas there was only one record from other countries such as Turkey. Besides, the most reported cases were isolated from blood (fungemia) and the most effective treatment protocol was with amphotericin B.

To the best of our knowledge, the case described here is the first report of a pityriasis versicolor-like superficial infection due to *N. albida*. In addition, treatment choices are limited for cryptococcal infections. The first choice of treatment for these infections is the combination of amphotericin B and flucytosine \[[@B11], [@B12]\]. Nonetheless, the treatment for infections due to *N. albida* is not well-defined, and amphotericin B has been mentioned to have limited efficacy in the treatment of *N. albida* \[[@B9]\]. *N. albida* shows various responses to different antifungal treatments. Therefore, there is no common treatment protocol for infections caused by this fungus.

###### 

Overview of 24 reported cases of Naganishia albida (1972--2017)

  **No**   **Age/sex/year**   **Location**   **Host status**                                                                     **Clinical presentation**   **Examination**           **Treatment**   **Outcome**     **Reference**
  -------- ------------------ -------------- ----------------------------------------------------------------------------------- --------------------------- ------------------------- --------------- --------------- ---------------
  1        68/ M/ 1972        USA            Not indicated                                                                       Pulmonary                   Culture                   AmB             Cured           \[20\]
  2        45/ M/ 1973        USA            Not indicated                                                                       Meningitis                  India ink, Culture        AmB             Cured           \[21\]
  3        29/M / 1980        USA            Juvenile rheumatoid arthritis, Alcoholic liver disease, receiving corticosteroids   Meningitis                  Culture                   AmB             Expired         \[22\]
  4        65/ F/ 1987        USA            Acute myelogenous leukemia                                                          Fungemia                    India ink                 AmB, 5FC        Expired         \[23\]
  5        NA/NA/1989         NA             Pemphigus foliaceus, steroid therapy                                                Fungemia                    Culture                   KET             Cured           \[24\]
  6        NA/NA/1993         USA            Receiving long-term hemodialysis                                                    Renal disease               Culture                   NA              NA              \[25\]
  7        38/M / 1996        France         AIDS                                                                                Septicaemia                 Culture                   FLU, ITC        Expired         \[26\]
  8        4/F / 1998         Tennessee      Acute Lymphocytic Leukemia                                                          Fungemia                    Not indicated             AmB             Cured           \[27\]
  9        70/ M/ 2000        U.K.           Sézary syndrome, Noninsulin-dependent diabetes                                      Cutaneous                   Culture, biopsy           FLU             Expired         \[16\]
  10       73/ F/ 2004        USA            Rheumatoid arthritis                                                                Pulmonary                   Culture, biopsy           FLU             Not indicated   \[1\]
  11       16/ F/ 2004        USA            AIDS                                                                                Scleral ulceration          Culture                   AmB, ITC        Cured           \[30\]
  12       23/M /2004         Korea          Renal transplant recipient                                                          Disseminated                Biopsy, Culture           FLU             Cured           \[17\]
  13       51/ M/ 2004        USA            Ddiabetes mellitus, lymphoma, Autologous progenitor cell transplant                 Not indicated               Culture                   AmB, ITC        Cured           \[33\]
  14       69/F/2005          USA            Corneal transplantation                                                             keratitis                   Culture                   Not indicated   Cured           \[2\]
  15       44/ M/2007         Turkey         Acute respiratory failure                                                           Pneumonia                   Histopathology, Culture   AmB             Cured           \[4\]
  16       14/M/2007          USA            Etanercept therapy                                                                  Cutaneous                   Culture                   FLU             Cured           \[10\]
  17       NA/NA/2011         USA            Immunosuppressed, palmopustular psoriasis                                           NA                          NA                        NA              NA              \[18\]
  18       0/ M/2011          Greece         Premature neonate                                                                   Fungemia                    NA                        AmB, 5FC        NA              \[29\]
  19       55/M/2013          USA            liver transplant recipient                                                          Fungemia                    Culture                   POS             Cured           \[19\]
  20       28/M/2014          China          AIDS                                                                                Encephalitis                India ink                 FLU             Expired         \[9\]
  21       57/M/2015          USA            Peritoneal Dialysis, hepatitis C, type 2 diabetes                                   Peritonitis                 Culture                   AmB             Not indicated   \[28\]
  22       45/M/2015          Taiwan         Hit by a plant                                                                      Keratitis                   PCR                       FLU, AmB        Cured           \[8\]
  23       83/M/2017          Hungary        Receiving methylprednisolone                                                        Cutaneous                   Histopathology            FLU             Not indicated   \[31\]
  24       26/M/2017          Iran           Immunocompetent                                                                     Superficial                 Culture, PCR              ITC             Cured           Present case

M, male; F, female; AmB, amphotericin B; FLU, fluconazole; ITC, itraconazole; KET, ketoconazole; 5FC, 5 flucytosine; POS, posaconazole.

NA = not available (Original publication could not be accessed, information gathered from related abstracts)

Recently, it has been indicated that *N. albida* is only sensitive to amphotericin B and itraconazole \[[@B4], [@B30], [@B31]\]. Other reports revealed side effects due to the conventional amphotericin B (1 mg/kg/day) therapy against *N. albida*, which led the therapy to change to itraconazole \[[@B32]\]. Besides, successful treatment with fluconazole has been reported in patients with cutaneous infections caused by *N. albida*using a mean treatment period of 56 days \[[@B16]\].

In the present case, after MIC approval, we chose 100 mg daily of itraconazole in a 10-day treatment period, which resulted in successful treatment. The three-month follow up of the patient revealed no relapse of the infection and no evidence of any clinical manifestations at the involved site. Furthermore, several factors such as the anatomical location of involvement, the power of immune system in host, and tissue damages can determine the proper medication and the required treatment duration for cryptococcal infections due to non-neoformans species \[[@B4], [@B5], [@B17], [@B33]\].

Conclusion
==========

In conclusion, *N. albida*was found to have the ability to cause superficial infections. The case presented here is the first report of successful detection and treatment of infection by this yeast. *N. albida*was detected by sequencing of ITS1-4 rDNA in this report and treated using oral itraconazole.
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